Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Merck KGaA Says PETACC-8 Study Of Erbitux Shows No Benefit At Interim Analysis

5/9/2012 3:40 AM ET

Merck KGaA (MKGAY.PK) revealed results from an interim analysis of the Phase III clinical trial PETACC-81.

The study investigated the potential clinical utility of Erbitux (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor.

The pre-specified interim analysis of the study did not support benefit in disease free survival for patients given Erbitux plus standard chemotherapy (FOLFOX 4) compared with patients treated with FOLFOX 4 alone. Therefore this interim analysis does not support the use of Erbitux for the adjuvant treatment of stage III colon cancer in this setting.

"We are disappointed not to see an improvement in disease free survival after 3.3 years of median follow up" said Professor Julien Taïeb from the Hôpital Européen Georges Pompidou, Paris, and the PETACC-8 Principal Investigator. "Unfortunately, since the introduction of FOLFOX as standard treatment, all attempts to further improve prevention of disease recurrence have proved unsuccessful. We look forward to sharing our data at future scientific congresses."

Click here to receive FREE breaking news email alerts for Merck KGaA and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks are turning in a lackluster performance in morning trading on Monday after showing a strong move to the upside last week. The major averages have been unable to sustain any significant moves, bouncing back and forth across the unchanged line. Leading U.S. economic indicators showed continued improvement in the month of March, according to a report released by the Conference Board on Monday, with the leading economic index rising by slightly more than expected. The Conference Board said its leading economic index rose by 0.8 percent in March after climbing by 0.5 percent in February. Healthcare products maker Kimberly-Clark Corp. (KMB) said that its first-quarter net income attributable to the company rose to $538 million from the prior year's $531 million, with earnings per share improving to $1.41 from $1.36 last year. Adjusted earnings for the quarter were $1.48 per share,...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.